Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Gross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Shares Outstanding (2016 - 2026)

Amphastar Pharmaceuticals has reported Shares Outstanding over the past 13 years, most recently at $61.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 29.74% year-over-year to $61.8 million; the TTM value through Dec 2025 reached $61.8 million, up 29.74%, while the annual FY2025 figure was $61.8 million, 29.74% up from the prior year.
  • Shares Outstanding for Q4 2025 was $45.6 million at Amphastar Pharmaceuticals, down from $61.7 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $61.7 million in Q3 2025 and troughed at -$10.3 million in Q1 2023.
  • A 5-year average of $47.4 million and a median of $57.8 million in 2022 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: surged 910.43% in 2021 and later tumbled 117.85% in 2023.
  • Year by year, Shares Outstanding stood at $56.4 million in 2021, then grew by 2.96% to $58.1 million in 2022, then rose by 2.2% to $59.4 million in 2023, then dropped by 19.82% to $47.6 million in 2024, then grew by 29.74% to $61.8 million in 2025.
  • Business Quant data shows Shares Outstanding for AMPH at $61.8 million in Q4 2025, $46.3 million in Q3 2025, and $61.6 million in Q2 2025.